Carvykti Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Carvykti market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be linked to the rising prevalence of cancer, growing investments in chimeric antigen receptor T-cell therapies, awareness and education initiatives, regulatory support for combination therapies, and the higher occurrence of hematological cancers.

The projected growth in the forecast period is driven by higher healthcare spending, the increasing prevalence of various types of blood cancer, the overall rise in cancer cases, growing awareness of chimeric antigen receptor T-cell therapy, and the rising incidence of multiple myeloma. Key trends during this period include the expanding adoption of chimeric antigen receptor T-cell therapies, the use of combination therapies, advancements in manufacturing technologies, product innovations, and the progress of next-generation CAR constructs.

The increasing prevalence of cancer is expected to drive the growth of the carvykti market. Cancer, a collection of diseases marked by the unchecked growth and spread of abnormal cells, can be fatal if left untreated. The rise in cancer cases is fueled by an aging population, lifestyle choices, environmental factors, and advancements in detection methods. Carvykti, a CAR T-cell therapy, offers a targeted treatment option for patients with relapsed or refractory multiple myeloma, improving outcomes for individuals with few treatment options. For example, the National Cancer Institute reported in May 2024 that, as of January 2022, there were an estimated 18.1 million cancer survivors in the U.S., with that number expected to increase to 22.5 million by 2032. As a result, the growing prevalence of cancer is expected to stimulate the growth of the carvykti market.

The growing emphasis on innovative therapies for relapsed or refractory multiple myeloma is a key trend in the carvykti market, particularly with the approval and development of CAR-T cell therapies such as Carvykti (ciltacabtagene autoleucel). In February 2022, Johnson & Johnson Services Inc., a U.S.-based healthcare company, received approval from the U.S. Food and Drug Administration (FDA) for Carvykti, a BCMA-targeted CAR-T cell therapy that uses two single-domain antibodies targeting B-cell maturation antigen (BCMA). This approval specifically addresses the treatment of adults with relapsed or refractory multiple myeloma after they have gone through four or more previous treatments. The approval provides a new option for patients with heavily pretreated multiple myeloma, offering the potential for long-lasting responses and the possibility of remaining free from anti-myeloma therapies for extended periods.

In April 2023, Johnson & Johnson Services Inc. and Legend Biotech, a U.S.-based biotechnology firm, partnered with Novartis to resolve supply challenges for their CAR-T therapy, Carvykti (cilta-cel), used to treat multiple myeloma. This collaboration aims to address ongoing issues with meeting demand, particularly due to a global shortage of viral vectors required for cell and gene therapies. Novartis AG, a pharmaceutical company based in Switzerland, develops innovative medications, including carvykti.

Major players operating in the carvykti market are Johnson & Johnson Services Inc., Legend Biotech, and Novartis AG.

North America was the largest region in the carvykti market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in carvykti report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the carvykti market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy designed to treat adults with relapsed or refractory multiple myeloma who have undergone at least four prior lines of therapy. It works by genetically modifying a patient's T cells to target and eliminate cancerous plasma cells that express the BCMA (B-cell maturation antigen) protein.

The primary type of Carvykti is cell therapy, specifically autologous T-cell therapy. This process involves collecting T-cells from the patient’s blood, genetically modifying them in a lab to enhance their ability to recognize and attack cancer cells, particularly those associated with multiple myeloma. Carvykti is used for various indications, including multiple myeloma and relapsed or refractory multiple myeloma, primarily in adult patients. It is distributed through hospital pharmacies, stem cell banks, and outpatient clinics.

The carvykti market research report is one of a series of new reports that provides carvykti market statistics, including the carvykti industry's global market size, regional shares, competitors with a carvykti market share, detailed carvykti market segments, market trends and opportunities, and any further data you may need to thrive in the carvykti industry. This carvykti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carvykti market consists of sales of kymriah, yescarta, breyanzi, pomalyst. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.